AUTHOR=Koch Rebecca M. , Kox Matthijs , Thijs Eleonora J. M. , Rahamat-Langendoen Janette C. , van de Veerdonk Frank L. , Gerretsen Jelle , Schloesser Joyce , Diavatopoulos Dimitri , Rimmelzwaan Guus F. , Netea Mihai G. , van der Hoeven Johannes G. , de Jonge Marien I. , Pickkers Peter
TITLE=Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans In Vivo
JOURNAL=Frontiers in Immunology
VOLUME=8
YEAR=2017
URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01600
DOI=10.3389/fimmu.2017.01600
ISSN=1664-3224
ABSTRACT=IntroductionThe effects of bacterial infections on the response to subsequent viral infections are largely unknown. This is important to elucidate to increase insight into the pathophysiology of bacterial and viral co-infections, and to assess whether bacterial infections may influence the course of viral infections.
MethodsHealthy male subjects received either bacterial endotoxin [Escherichia coli-derived lipopolysaccharide (LPS), 2 ng/kg, n = 15] or placebo (n = 15) intravenously, followed by intranasal Fluenz (live-attenuated influenza vaccine) 1 week later.
ResultsLPS administration resulted in increased plasma cytokine levels and development of endotoxin tolerance in vivo and ex vivo, illustrated by attenuated cytokine production upon rechallenge with LPS. Following Fluenz administration, infectivity for the Fluenz A/B strains was similar between the LPS–Fluenz and placebo–Fluenz groups (13/15 subjects in both groups). Also, the Fluenz-induced increase in temperature and IL-6, G-CSF and IP-10 concentrations in nasal wash were similar between both groups.
ConclusionWhile endotoxemia profoundly attenuates the immune response upon a second LPS challenge, it does not influence the Fluenz-induced immune response. These results suggest immune suppression after bacterial infection does not alter the response to a subsequent viral infection.